Evidence map›Paper›PMID 30386849›Full record

ArticleJournal of the Belgian Society of Radiology2018

Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study.

Hiroaki Takahashi, Sota Masuoka, Katsuhiro Nasu, Kensaku Mori, Takahiro Kojima, Kuniaki Fukuda, Kazuhiro Takahashi, Toshitaka Ishiguro, Takahiro Hosokawa, Manabu Minami

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Belgian Society of Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hiroaki TakahashiUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
Sota MasuokaUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
Katsuhiro NasuUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
Kensaku MoriUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
Takahiro KojimaUniversity of Tsukuba, Faculty of Medicine, Department of Urology, Ibaraki, JP.
Kuniaki FukudaUniversity of Tsukuba, Faculty of Medicine, Department of Gastroenterology, Ibaraki, JP.
Kazuhiro TakahashiUniversity of Tsukuba, Faculty of Medicine, Department of Gastroenterological and Hepatobiliary Surgery, Ibaraki, JP.
Toshitaka IshiguroUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
Takahiro HosokawaSaitama Children's Medical Center, Department of Radiology, Saitama, JP.
Manabu MinamiUniversity of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.
University of Tsukuba · JPSaitama Children's Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR).

methodsWe retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who underwent sorafenib therapy for 31 to 1225 days (median, 100 days). PVR was estimated by two independent readers using CT volumetry.

resultsThe sum of all prostate volumes measured by reader 1 was 24.2 ± 13.8 cm

conclusionOur study demonstrated significant PVR with sorafenib treatment in patients regardless of the presence of BPH and underlying liver dysfunction.

Indexed as

Adverse effectBenign Prostatic HyperplasiaProstateSorafenib

Identifiers

PMID30386849
PMCPMC6208293
OpenAlexW2898326720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.